Genzyme, a global biotechnology company, launches a plan to develop therapies for neglected diseases, (e.g. malaria, TB), giving away the intellectual property.
This case targets the decision of which disorders, which ventures, and which markets should management decide to fund. However the larger issue is how this program urbanized under the umbrella part Genzyme's corporate social responsibility fits into its international competitive strategy.
PUBLICATION DATE: August 20, 2009 PRODUCT #: 910407-PDF-ENG
This is just an excerpt. This case is aboutĀ GLOBAL BUSINESS